Kailera Therapeutics, Inc. (KLRA) vs Maze Therapeutics, Inc. (MAZE)
A side-by-side comparison of Kailera Therapeutics, Inc. and Maze Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
KLRA
Kailera Therapeutics, Inc.
$10.87HealthcareDelayed quote: Oct 6, 2026, 10:50 AM EDT
MAZE
Maze Therapeutics, Inc.
$26.16HealthcareDelayed quote: Oct 6, 2026, 10:50 AM EDT
Total return — KLRA vs MAZE
growth of $100 · dividends reinvested · last 1yKLRA -58.3% (-58.3%/yr)MAZE -5.9% (-5.9%/yr)MAZE compounded faster over this window
KLRA MAZE
KLRA vs MAZE: by the numbers
- •MAZE is the larger company ($1.45B vs $1.41B market cap).
- •Both run net losses; KLRA's is the smaller (0.00% vs -667.95% net margin).
Metrics side by side
Valuation
| Metric | KLRA | MAZE |
|---|---|---|
| P/S ratio | N/A | 72.38 |
| P/B ratio | 1.26 | 3.19 |
Profitability
| Metric | KLRA | MAZE |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | -667.95% |
| ROE | N/A | -29.48% |
| ROIC | -24.52% | -28.63% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.